Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced ...

Peripheral vascular embolization solution developer Instylla announced today that it appointed Sean Boyle as its new CEO.

Stryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 ...

Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet ...